Navigation Links
Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
Date:11/6/2008

------------------------------

Chordoma 5* SD

-------------------------------------------------------------------------

Unspecified Spindle Cell 5* SD

-------------------------------------------------------------------------

* patients still on study

An oral presentation covering results of the trial (REO 014) is also scheduled to be delivered at the Connective Tissue Oncology Society (CTOS) annual meeting, being held in London, U.K. from November 13-15, 2008.

The slides will be available on the Oncolytics' website after the presentation.

Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research is also scheduled to present a poster at the CTOS meeting entitled "Systemic Administration of REOLYSIN Inhibits Growth of Human Sarcoma Xenografts Alone and in Combination with Cisplatin and Radiation."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), the Company's analysis of the results of the Phase II trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
2. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
3. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
4. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
5. Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
6. Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
7. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
8. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
9. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
10. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
11. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Staying ... technology to craft a digital product that makes the ... partnered with Global Biological Standards Institute (GBSI) to redesign ... modern, clean, and most importantly, strategy-based. , "Biomedical research ... person - much less to promote it in a ...
(Date:4/21/2015)... 21, 2015 Invetech , a ... automation, and contract manufacturing, and  NanoCellect Biomedical, ... and cell sorting technology for life science researchers, ... flow cytometry platform. Headquartered in ... developed a microchip-based cell sorting technology. NanoCellect,s flow ...
(Date:4/21/2015)... April 21, 2015  Tute Genomics, a leading provider of ... Josh Forsythe as VP of Marketing. Mr. Forsythe is ... significant expansion in its commercial operations over the last two ... " Josh Forsythe is a tremendous addition to the ... CEO of Tute Genomics. "Josh,s vast experience commercializing software technology ...
(Date:4/21/2015)... and RESEARCH TRIANGLE PARK, N.C. ... Corporation (NASDAQ: UTHR ) announced today that it ... market open on Tuesday, April 28, 2015. ... April 28, 2015, at 9:00 a.m. Eastern Time.  The ... dialing 1-970-315-0533.  A rebroadcast of the teleconference will be ...
Breaking Biology Technology:Visceral Tells GBSI’s Story Within 30 Seconds of Attention 2Visceral Tells GBSI’s Story Within 30 Seconds of Attention 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... a biotechnology company developing orally-available antiviral therapeutics, today announced that ... Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and ... Adenovirus Disease Following H em a ... T ransplantation [HSCT]).The company also announced that the U.S. ...
... in cat litter and other applications. The extraordinary properties of ... its scarcity in the Earth,s crust: only a few mines ... Spain, the world,s biggest exporter of this material. Sepiolite ... to filter and purify wine, but our understanding at the ...
... July 12, 2011 The J. R. Simplot ... all-native biotechnology platform for improving crops, leading to ...   http://photos.prnewswire.com/prnh/20110712/SF33047LOGO )   Innate™ Technology ... with a plant,s own genes to enhance desirable ...
Cached Biology Technology:Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 2Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 3Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 4Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 5Cat litter to become an edible product? 2
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... Latin America . Annual estimates and forecasts ...
(Date:3/18/2015)... -- As mobile payments become more prevalent amongst ... apps continue to be introduced into the market place at ... industry in focus today are:  NXT-ID, Inc. (NASDAQ: ... ), Apple Inc. (NASDAQ: AAPL ), Google Inc. ... FB ) NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... to the prevailing view, the hormone leptin, which is critical ... mass and suppress appetite by acting mainly through serotonin pathways ... Cell by Yale School of Medicine researchers and ... that leptin acts primarily in the hypothalamus. "Our ...
... French . Nineteen McGill University researchers ... mathematics are among the 181 newly appointed or renewed Canada ... Minister of State (Science and Technology.) McGill received ... a total of $17,600,000, the largest amount received by any ...
... A NASA team is developing a transparent coating that ... prevent dirt from sticking to the surfaces of spaceflight ... Materials engineers at NASA,s Goddard Space Flight Center ... coating that can survive the harsh space environment and ...
Cached Biology News:Researchers identify new brain pathway for regulating weight and bone mass 2McGill garners 19 Canada Research Chairs and more than $17 million in funding 2McGill garners 19 Canada Research Chairs and more than $17 million in funding 3Lotus-plant-inspired dust-busting shield to protect space gear 2Lotus-plant-inspired dust-busting shield to protect space gear 3
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... Clone/PAD: ZMD.414. Immunogen: Synthetic peptide derived ... and rat mTOR (Mammalian target of rapamycin ... the human mTOR protein. On Western ... ~235 kDa. Reactivity: Human (positive control: ...
...
Biology Products: